Valtrax Research is opening — leave your email and we'll ping you the moment the first compounds are listed.
Every lot tested by Janoshik Analytical
Cart
Your cart is empty
Find
Valtrax Research is opening — leave your email and we'll ping you the moment the first compounds are listed.
Your cart is empty
Hexapeptide · GHS-R1a agonist
Also known as Pralmorelin · KP-102 · GPA-748
Growth hormone-releasing peptide-2, a synthetic hexapeptide agonist at the ghrelin receptor (GHS-R1a). Supplied as a lyophilized powder for research purposes only.
Catalog opens shortly. Leave your address and we will ping you the moment this compound is orderable.
Tested lot by lot at ≥99% purity. The Janoshik certificate for your lot is emailed with the order.
Everything Valtrax Research ships is bench material for in-vitro work. None of it is a drug, a supplement, a cosmetic, or a medical device, and none of it is intended for human or animal use, ingestion, or administration. Placing an order is your confirmation that you are a qualified researcher buying for lawful research, under every Canadian law and regulation that applies to you.
Six residues, half of them unnatural: D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂, supplied as the acetate salt. GHRP-2 is a synthetic growth hormone secretagogue that works the ghrelin receptor (GHS-R1a) rather than the GHRH receptor — a distinction established directly in receptor work, and the reason it is studied as a separate axis into somatotroph signalling rather than as another GHRH analogue.
The D-amino acids and the C-terminal amide are the engineering. They are what keep a six-residue peptide intact long enough to produce a measurable response, and they are why this compound became the reference secretagogue in the GHRP series.
Two threads run through the literature. The first is endocrine: how cleanly a small synthetic peptide engages GHS-R1a and what the somatotroph does in response, measured as GH release and used diagnostically. The second is everything else the ghrelin receptor touches — appetite signalling and inflammatory readouts — plus a steady analytical-chemistry thread on detecting the compound in seized and adulterated material.
GHRP-2 binds GHS-R1a, the receptor ghrelin occupies, and the downstream readout is somatotroph activation and growth hormone release. Receptor work in GC cells showed the response survives when the GHRH receptor is taken out of the picture, which is what separates this pathway from GHRH analogues such as sermorelin or tesamorelin.
Beyond the endocrine readout, published work follows the ghrelin-receptor consequences that come with it: food-intake response in healthy volunteers, and inflammatory markers in arthritis models. The compound also shows up in analytical chemistry literature as a detection target in seized product and adulterated supplements.
The compound emerged from the growth-hormone-releasing-peptide line that began with the enkephalin-derived secretagogues of the 1980s, and was developed under the code KP-102 with its pharmacology characterized in that program. A 2004 profile catalogued it under the generic name pralmorelin alongside its several development codes.
Its most durable role has been diagnostic: GH-stimulation testing for hypothalamic-pituitary disorder, including work in pediatric and adolescent cohorts, where a reliable, short-acting secretagogue is more useful than a long one.
Doi, N. et al. (2004). Pharmacological characteristics of KP-102 (GHRP-2), a potent growth hormone-releasing peptide.
PubMedChen, C. et al. (1998). Growth hormone-releasing peptide-2 (GHRP-2) does not act via the human growth hormone-releasing factor receptor in GC cells.
PubMedLaferrère, B. et al. (2005). Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men.
PubMedGranado, M. et al. (2005). Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats.
PubMedSuzuki, S. et al. (2022). Clinical Usefulness of the Growth Hormone-Releasing Peptide-2 Test for Hypothalamic-Pituitary Disorder.
PubMedIdentity, purity, and net content are established by independent Janoshik verification, and the certificate for your lot travels with the order.
Janoshik Analytical, a laboratory Valtrax does not own, runs the testing — identity by mass spectrometry, purity by RP-HPLC at ≥99%. The certificate covering the lot you receive is also emailed with your order.
Same Shelf
